title: Maraviroc Reduces Arterial Stiffness in PI-Treated HIV-infected Patients.
abstract: The Δ32-CCR5 deletion of the CCR5 receptor is protective toward coronary artery pathology and myocardial infarction. Maraviroc (MVC), a CCR5 antagonist, was recently introduced in the therapy of HIV infection; we evaluated whether this drug could modulate the atherosclerotic burden in aviremic PI-treated HIV-positive individuals who underwent MVC intensification. Thus, the effect of MVC on intima media thickness, arterial stiffness, metabolic parameters, pro-inflammatory cytokines, endothelial dysfunction, and microbial traslocation markers was analyzed in 6 aviremic PI-treated HIV-positive individuals and were compared to those obtained in 9 additional aviremic PI-treated subjects that were enrolled retrospectively from our outpatients cohort. MVC intensification resulted in a significant reduction in intima media thickness, pulse wave velocity and triglycerides compared to baseline. Notably, MVC was also associated with a significant reduction of IL-6, microbial translocation indexes, sICAM and sVCAM; these changes were maintained throughout the 6 months of MVC intensification. No significant modifications were observed in CD4 counts, HIV viral load, and cholesterolemia. Results herein support a role of CCR5 antagonists in reducing the cardiovascular risk in HIV-infection. The hampering of inflammation, microbial translocation and the improvement of endothelial function could justify the protective role of CCR5 antagonists on atherosclerotic burden.
authors.affiliation: Infectious Diseases Unit, L. Sacco Hospital, via G.B. Grassi, 74; 20157 Milano, Italia.
authors.forename: Stefania
authors.initials: S
authors.lastname: Piconi
authors.affiliation: Infectious Diseases Unit, L. Sacco Hospital, via G.B. Grassi, 74; 20157 Milano, Italia.
authors.forename: Daria
authors.initials: D
authors.lastname: Pocaterra
authors.affiliation: Chair of Immunology, Department of Biomedical and Clinical Sciences "L. Sacco", University of Milan, Milan, Italy.
authors.forename: Veronica
authors.initials: V
authors.lastname: Rainone
authors.affiliation: Infectious Diseases Unit, L. Sacco Hospital, via G.B. Grassi, 74; 20157 Milano, Italia.
authors.forename: Maria
authors.initials: M
authors.lastname: Cossu
authors.affiliation: Chair of Immunology, Department of Biomedical and Clinical Sciences "L. Sacco", University of Milan, Milan, Italy.
authors.forename: Michela
authors.initials: M
authors.lastname: Masetti
authors.affiliation: Infectious Diseases Unit, L. Sacco Hospital, via G.B. Grassi, 74; 20157 Milano, Italia.
authors.forename: Giuliano
authors.initials: G
authors.lastname: Rizzardini
authors.affiliation: Department of Physiopathology Medical-Surgery and Transplantation, University of Milan, Milan, and Don C. Gnocchi Foundation ONLUS, IRCCS, Milan, Italy.
authors.forename: Mario
authors.initials: M
authors.lastname: Clerici
authors.affiliation: Chair of Immunology, Department of Biomedical and Clinical Sciences "L. Sacco", University of Milan, Milan, Italy.
authors.forename: Daria
authors.initials: D
authors.lastname: Trabattoni
mesh_terms: D050197:Atherosclerosis / Q000139:chemically induced / Q000517:prevention & control*; D059168:Carotid Intima-Media Thickness; D016022:Case-Control Studies; D003510:Cyclohexanes / Q000494:pharmacology / Q000627:therapeutic use*; D023581:HIV Fusion Inhibitors / Q000494:pharmacology / Q000627:therapeutic use*; D015658:HIV Infections / Q000188:drug therapy*; D017320:HIV Protease Inhibitors / Q000009:adverse effects* / Q000627:therapeutic use; D006801:Humans; D008297:Male; D000077592:Maraviroc; D012307:Risk Factors; D016896:Treatment Outcome; D014230:Triazoles / Q000494:pharmacology / Q000627:therapeutic use*; D059289:Vascular Stiffness / Q000187:drug effects*
chemical_list: D003510:Cyclohexanes; D023581:HIV Fusion Inhibitors; D017320:HIV Protease Inhibitors; D014230:Triazoles; D000077592:Maraviroc